

1 April 2026

Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")

Total Voting Rights

Coiled Therapeutics plc (AIM:COIL), announces, following the Company's recent successful Admission to trading on AIM and for the purpose of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 425,856,539 ordinary shares of 1p each ("Ordinary Shares") with voting rights.

The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 425,856,539. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Coiled Therapeutics plc

Sotirios Stergiopoulos (Chairman)
Sridhar Vempati (CEO)

Via Burson
Buchanan

**SP Angel Corporate Finance LLP (Nominated Adviser
and Joint Broker)**

+44 (0)20 3470 0470

David Hignell / Adam Cowl / Devik Mehta (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

Shard Capital Partners LLP (Joint Broker)

+44 (0)20 4530 6926

Damon Heath

CPS Capital Group Pty Ltd (Joint Broker)

+61 (0)8 9223 2222

Jason Peterson / David Valentino

Burson Buchanan (Public Relations)

+44 (0)20 7466 5000

Henry Harrison Topham / Jamie Hooper / Toto Berger

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.

The asset is currently in an ongoing Phase I open-label dose-escalation study and early clinical signals have shown encouraging anti-tumour activity and a benign safety profile, with the Company planning to initiate dose expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRWPUAWWUPQGQG